Nasdaq · Biotech stocks database
EYPT — EyePoint, Inc. ☆
EYPT (EyePoint, Inc.) stock: $0.36, $31.0M market cap, $180.5M cash, -$149.5M EV, $36.9M fully diluted market cap. Lead program: EYP-1901 (Wet Age Related Macular Degeneration), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
Balance sheet
Cash $180.5M Debt $0.0M Net cash $180.5M Enterprise value -$149.5M Basic shares 86.2M shares Fully diluted shares 102.5M shares Fully diluted market cap $36.9M Cash per share $2.09 Quarterly burn $62.3M Cash runway 2.9 quarters
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-06-30.
Price history Loading EYPT daily closes…
Loading price history…
Recently reported DURAVYU (vorolanib intravitreal insert) Phase 3 Negative · 2026-10-19
LUCIA · wet age-related macular degeneration (wet AMD)
Primary: Statistical non-inferiority in mean change in best corrected visual acuity (BCVA) versus on-label 2 mg aflibercept control — Did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept, despite demonstrating visual improvement
· Superior 38% reduction in treatment burden (nominal p-value <0.0001)
· 52% of eyes supplement-free up to Week 56
· 71% receiving zero or one supplement up to Week 56
· Strong anatomic control at Week 56
Safety: Continued favorable safety profile for DURAVYU with redosing
DURAVYU (vorolanib intravitreal insert) Phase 3 Negative · 2026-08-17
LUGANO · wet age-related macular degeneration
Asset data not yet available for this company.
Pipeline Lead drug EYP-1901 Lead indication Wet Age Related Macular Degeneration Lead phase Phase 3 Active trials 4
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.